Precision targeted therapy of ovarian cancer

Justin Sapiezynski; Oleh Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko

doi:10.1016/j.jconrel.2016.10.014

Precision targeted therapy of ovarian cancer

J Control Release. 2016 Dec 10:243:250-268. doi: 10.1016/j.jconrel.2016.10.014. Epub 2016 Oct 14.

Authors

Justin Sapiezynski¹, Oleh Taratula², Lorna Rodriguez-Rodriguez³, Tamara Minko⁴

Affiliations

¹ Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, United States.
² Department of Pharmaceutical Sciences, Oregon State University, Portland, OR 97239, United States.
³ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, United States; Department of Obstetrics and Gynecology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, United States.
⁴ Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, United States; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, United States. Electronic address: minko@rci.rutgers.edu.

Abstract

The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.

Keywords: Genetic profiling; Nanotechnology; Personalized medicine; Targeted therapy; siRNA.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Animals
Female
Humans
Molecular Targeted Therapy*
Nanotechnology / methods*
Ovarian Neoplasms / diagnosis
Ovarian Neoplasms / therapy*
Precision Medicine / methods

Grants and funding

R01 CA138533/CA/NCI NIH HHS/United States